Evidence map›Paper›PMID 32527266›Full record

ArticleJournal of nanobiotechnology2020

Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials.

Hong Song, Guo-Hui Cai, Jian Liang, Di-Shu Ao, Huan Wang, Ze-Hong Yang

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Polymeric Hydrogels for In Vitro 3D Ovarian Cancer Modeling.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hong SongCollege of Basic Medicine, Zunyi Medical University, No.201 Dalian Road, Huichuan District, Zunyi, Guizhou, 563003, China.
Guo-Hui CaiCollege of Basic Medicine, Zunyi Medical University, No.201 Dalian Road, Huichuan District, Zunyi, Guizhou, 563003, China.
Jian LiangSchool of Resources and Environment, ABA Normal University, Shuimo Town, Wenchuan County, Aba Prefecture, Sichuan, 623002, China.
Di-Shu AoCollege of Basic Medicine, Zunyi Medical University, No.201 Dalian Road, Huichuan District, Zunyi, Guizhou, 563003, China.
Huan WangCollege of Basic Medicine, Zunyi Medical University, No.201 Dalian Road, Huichuan District, Zunyi, Guizhou, 563003, China.
Ze-Hong YangWest China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, No.17 People's South Road, Chengdu, Sichuan, 610041, China. yangzehong@scu.edu.cn.
Zunyi Medical University · CNAba Teachers University · CNWest China Medical Center of Sichuan University · CN

Funding

National Natural Science Foundation of China 81160290National Natural Science Foundation of China 81660340
6 · The paper itself

Abstract

backgroundOvarian cancer is a highly aggressive malignant disease in gynecologic cancer. It is an urgent task to develop three-dimensional (3D) cell models in vitro and dissect the cell progression-related drug resistance mechanisms in vivo. In the present study, RADA16-I peptide has the reticulated nanofiber scaffold networks in hydrogel, which is utilized to develop robust 3D cell culture of a high metastatic human ovarian cancer HO-8910PM cell line accompanied with the counterparts of Matrigel and collagen I.

resultsConsequently, HO-8910PM cells were successfully cultivated in three types of hydrogel biomaterials, such as RADA16-I hydrogel, Matrigel, and collagen I, according to 3D cell culture protocols. Designer RADA16-I peptide had well-defined nanofiber networks architecture in hydrogel, which provided nanofiber cell microenvironments analogous to Matrigel and collagen I. 3D-cultured HO-8910PM cells in RADA16-I hydrogel, Matrigel, and collagen I showed viable cell proliferation, proper cell growth, and diverse cell shapes in morphology at the desired time points. For a long 3D cell culture period, HO-8910PM cells showed distinct cell aggregate growth patterns in RADA16-I hydrogel, Matrigel, and collagen I, such as cell aggregates, cell colonies, cell clusters, cell strips, and multicellular tumor spheroids (MCTS). The cell distribution and alignment were described vigorously. Moreover, the molecular expression of integrin β1, E-cadherin and N-cadherin were quantitatively analyzed in 3D-cultured MCTS of HO-8910PM cells by immunohistochemistry and western blotting assays. The chemosensitivity assay for clinical drug responses in 3D context indicated that HO-8910PM cells in three types of hydrogels showed significantly higher chemoresistance to cisplatin and paclitaxel compared to 2D flat cell culture, including IC

conclusionBased on these results, RADA16-I hydrogel is a highly competent, high-profile, and proactive nanofiber scaffold to maintain viable cell proliferation and high cell vitality in 3D cell models, which may be particularly utilized to develop useful clinical drug screening platform in vitro.

Indexed as

Antineoplastic AgentsBiocompatible MaterialsCell Culture TechniquesCell Line, TumorCell ProliferationFemaleHumansHydrogelsNanofibersOvarian NeoplasmsTumor MicroenvironmentAntineoplastic AgentsBiocompatible MaterialsHydrogels3D cell cultureCell growth patternChemosensitivityHO-8910PM cellsHydrogelNanofiber

Identifiers

PMID32527266
PMCPMC7291456
OpenAlexW3034753503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.